Tuesday, September 26, 2023 11:15:42 AM
at 10:06 am..
We thank you for being a shareholder and for caring about the health and welfare of BioAdaptives. Our interests are similar to yours.
As a fully-reporting public OTC company, as you surely know, we have very specific obligations to the public and to the SEC, as well as to Company insiders, for timely reporting of material events. As such, we recently filed our 2nd quarter 2023 Form 10-Q as required by the SEC as the period's general update regarding Company activity and status. It is available on-line for all to review. We also file SEC 8-K's when a significant event or change occurs for the public to be advised. Other SEC forms are filed as required, and all are posted on-line for anyone to review.
We are required to keep everyone equally informed regarding Company events. No one gets special reporting or information. As such, we issue press releases through public media for all to see when any significant event or Company change occurs. However, we must be cautious not to make up news, but to timely report it once it occurs.
BioAdaptives is aware of our stockholder support. We have over 13,000 owners of the Company and we want each one, as well as the public, to be as informed as possible. We take that very seriously, and, again, we thank you for your interest and concern and participation.
Please feel free to pass along your thoughts at any time. We appreciate it.
Respectfully,
Bob Ellis, President
BioAdaptives, Inc.
Las Vegas, Nevada USA
rwe@bioadaptives.com
Recent BDPT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:28 PM
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 10/11/2023 07:59:24 PM
- Form 1-Z - • Edgar (US Regulatory) • 08/24/2023 06:40:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:16:40 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM